1. The 2022 Starting Line

In 2022, the post-COVID dust was settling on a sector the pandemic had transformed: pharmacies had become vaccination infrastructure, health and wellness spending had structurally re-rated, and two JSE-listed champions — Clicks and Dis-Chem — emerged with strengthened consumer trust. But the sector carried scars and questions.

Clicks entered 2022 still healing reputational wounds and facing investor questions about how much further its pharmacy rollout could run. Dis-Chem was navigating its first years as a public company under founder leadership, with a wage-moratorium controversy (2022) testing its brand, and a leadership transition looming as the Saltzman founders prepared to hand over. The supermarket groups treated pharmacy as an afterthought: Pick n Pay had just sold its 25 pharmacies to Clicks (2021), Shoprite’s MediRite was ticking along quietly, and SPAR’s pharmacy ambitions were embryonic. Independent community pharmacies — thousands of them — faced the relentless squeeze of regulated medicine pricing and corporate chain expansion.

Four years on, the sector looks very different: the duopoly is bigger and stronger, but for the first time in a decade, serious new attackers have entered the dispensary. Below is the reckoning.

2. The 2022–2026 Scoreboard

3. Clicks Group — The Fortress Triumphed

Clicks spent 2022–2026 doing what Clicks does: opening stores and pharmacies on schedule, compounding ClubCard data, expanding margin — and returning billions to shareholders. The result is the most complete health-and-beauty machine in Africa. But early 2026 delivered a rare stumble.

What changed since 2022

• Relentless network growth: from ~840 stores in 2022 to the milestone 1,000th store (Feb 2026, now 1,003) and the 800th pharmacy (opened in Oudtshoorn, April 2026) — 22 years after its first pharmacy in 2004. 53.6% of SA households now live within 5km of a Clicks pharmacy.
• FY2025 (Aug 2025) excellence: turnover R47.8bn (+5.3%); trading margin up 60bps to 9.8% (+160bps over five years); diluted HEPS +14.1%; total dividend +14.2% to 886c; industry-leading ROE of 49.2%; R2.7bn returned via dividends and buybacks.
• The loyalty data machine: ClubCard — 30 years old in 2025 — grew to 12.9m active members (Feb 2026), contributing 83.7% of Clicks sales; R7.5bn in lifetime cashback paid. Private label hit R9.7bn (+10.7%), targeting 35% of front-shop sales.
• Portfolio sharpening: baby category leadership extended (23.1% share; standalone Clicks Baby stores +23%); UniCare specialised pharmacies launched; UPD doubled its electric delivery fleet to 85 vehicles with 86% of wholesale deliveries off fuel.
• The 2026 wobble: H1 FY2026 (Feb 2026) showed turnover +7.4% to R24.9bn and HEPS +8.1% — respectable, but warehouse-management-system (WMS) delays at the Cape Town DC hurt festive availability, inventory days rose, and full-year guidance of 4–9% HEPS growth disappointed. The share fell from R332 (Jan 2026) to ~R248 by late May — roughly R19.7bn of market value surrendered in five months.

4. Dis-Chem — The Ecosystem Builder Triumphed

Dis-Chem’s four years were a successful identity change: from founder-run pharmacy chain to professionally managed, data-led health ecosystem — wholesaler, franchisor, insurer and retailer at once.

What changed since 2022

• The founder handover: Ivan Saltzman stepped down (2023) after four decades, succeeded by CFO-turned-CEO Rui Morais — a generational transition executed without losing momentum.
• FY2025 (Feb 2025) breakout: revenue +8.0% to R39.2bn; HEPS +20.0% to 137.5c — powered by “staffing framework 1.0” payroll discipline that drove operating profit +18.3%, well ahead of sales.
• The wholesale flywheel: CJ Distribution revenue +11.1% (H1 FY2026 to R16.8bn); external sales to ~1,350 independent pharmacies +7.9%; The Local Choice franchise up to 258 stores (+16.5% sales) — Dis-Chem now profits even when independents win the customer.
• Ecosystem moves: Dis-Chem Life launched (Feb 2025) selling life and funeral cover with “market-leading early metrics”; the “X, bigly labs” innovation unit established to build an integrated health-and-wellness platform; a new Midrand warehouse acquired (Dec 2024).
• H1 FY2026 (Aug 2025) consistency: revenue +8.7% to R21.3bn; HEPS +9.0%; 17 new pharmacies (302 total); retail dispensary share at 24.7%; September–October trading +9.7% — momentum intact into the second half.

5. SPAR Health — The New Invader Rising Challenger

The biggest strategic surprise of the period: a grocery wholesaler deciding that pharmacy is its next growth engine — and backing the claim with acquisitions, distribution investment and a public 250-store target.

What changed since 2022

• From sideline to strategy: Pharmacy at SPAR grew to 125+ stores; SPAR Health (incorporating S Buys wholesale and Scriptwise courier pharmacy) became the group’s fastest-growing adjacency at +13.2% in FY2025.
• The Aptekor acquisition (approved Oct 2025): a 50-year-old Western Cape pharmaceutical wholesaler serving pharmacies, hospitals and doctors — phase one of a national wholesaling build-out, with a Durban-based wholesaler acquisition in advanced stages and a KZN DC planned for H2 FY2026.
• The declared ambition: 170 pharmacies by September 2026, 250 by 2028 — which would carry SPAR past MediRite into clear third place; plus a “bespoke wellness concept” planned across pharmacies and SPAR stores.
• The model edge: like everything SPAR, the pharmacies ride on independent retailers and group wholesale — an asset-light rollout the corporate chains cannot copy, aimed squarely at communities where Clicks and Dis-Chem are thin.

6. Shoprite MediRite — The Quiet Grocer’s Pharmacy Steady — Underpowered

Africa’s biggest retailer owns a pharmacy chain, a pharmaceutical wholesaler (Transpharm) and 1.2 billion annual customer visits — yet pharmacy remains its least weaponised asset.

What changed since 2022

• Steady expansion: MediRite grew to ~144 outlets, including standalone MediRite Plus destination pharmacies launched to compete beyond the in-store counter.
• Infrastructure in place: Transpharm provides wholesale supply; Shoprite’s unmatched store traffic and Xtra Savings data (33.7m members) offer cross-sell potential no rival can match — largely untapped for healthcare.
• Strategic posture: pharmacy functions as a footfall and convenience service inside the grocery flywheel rather than a declared growth pillar — conspicuously absent from the group’s headline investment narrative compared with Sixty60, Petshop Science or Money Market.

7. The Independents — Link, Alpha Pharm & the Community Pharmacy Under Siege

South Africa’s community pharmacies remain the sector’s human face — and its squeezed middle. Their survival strategy has been consolidation under banners and, ironically, deepening dependence on the very corporates competing with them.

What changed since 2022

• Banner consolidation accelerated: Alpha Pharm (350+ stores, Swiss-owned via Shogun Holding since 2015) remains the largest independent retail group; Link (300+ stores) licenses its brand from Clicks’ UPD — collective scale as defence.
• The wholesale embrace: ~1,350 independents now buy through Dis-Chem’s wholesale arm (+7.9% in H1 FY2026); others through UPD, Aptekor (now SPAR) and S Buys — meaning every major chain now profits from the independents’ baskets even while competing for their customers.
• The franchise migration: The Local Choice (Dis-Chem) grew to 258 stores — independents trading independence for buying power, branding and systems; SPAR’s model offers a similar refuge.
• The structural squeeze: Single Exit Price regulation caps dispensing economics; medical-aid network designations steer scripts to chains; pharmacist scarcity and security costs hit small operators hardest. The truly unaffiliated corner pharmacy keeps thinning.

8. The Absentees — Pick n Pay, Woolworths & the Ones Who Left Exited / Absent

Strategy is also defined by who chose not to fight. Two of SA retail’s biggest names sat out the dispensary wars — decisions that look more consequential with each passing year.

• Pick n Pay: sold its 25 pharmacies to Clicks in 2021 mid-crisis — rational triage at the time, but it surrendered the script-driven footfall and ageing-customer lock-in that rivals now monetise. A turnaround business has no capital for re-entry; the absence is effectively permanent this decade.
• Woolworths: plays only at the wellness-adjacent edge (vitamins, supplements, WCellar-style health ranges, Absolute Pets) — premium front-shop without dispensary. Defensible, but it cedes the medicines wallet of its own affluent base to Clicks and Dis-Chem, whose beauty halls increasingly attack Woolworths’ turf from the other side.
• Massmart/Walmart: Makro’s pharmacy presence remains marginal; if Walmart imports its US pharmacy-superstore doctrine, that calculus could change — one to watch beyond 2026.

10. July–December 2026: What Comes Next

The second half of 2026 brings a loaded calendar: Clicks’ redemption results, Dis-Chem’s expansion sprint, SPAR’s first public pharmacy deadline — and a consumer squeezed by fuel-led inflation deciding every basket. The RIDBS read:

Player	Key H2 2026 events	RIDBS base case	Biggest risk
Clicks	FY26 results (Oct); WMS stabilisation; festive availability test; concept-store pilots	Lands mid-guidance (~6–7% HEPS); supply chain fixed by peak season; rollout on schedule	Second festive stumble; multiple de-rating deepens
Dis-Chem	32-store expansion sprint; H1 FY27 interims (~Oct); Life & ecosystem metrics	High single-digit revenue growth; ecosystem narrative strengthens	Cost-leverage story matures; front-shop discretionary softness
SPAR Health	170-pharmacy target (Sept); KZN DC go-live; Durban wholesaler close	Target substantially met; clear #3 position consolidating	Integration strain; wholesale price war with UPD/CJ
Shoprite MediRite	FY26 results (Sept); possible healthcare strategy signals	Steady expansion continues; no declared offensive — yet	Strategic drift while rivals lock up the script
Independents	Wholesale terms battles; banner/franchise migration	Continued consolidation under TLC, Link, Alpha, SPAR	Funder network exclusions; pharmacist scarcity; NHI uncertainty

11. Summary & The RIDBS View